Moonlake Immunotherapeutics AG
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 2021-03-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.moonlaketx.com
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
- First Posted Date
- 2025-01-10
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- MoonLake Immunotherapeutics AG
- Target Recruit Count
- 35
- Registration Number
- NCT06768671
- Locations
- 🇺🇸
Clinical Site, Norfolk, Virginia, United States
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- MoonLake Immunotherapeutics AG
- Target Recruit Count
- 960
- Registration Number
- NCT06641076
- Locations
- 🇺🇸
Clinical Site, Beckley, West Virginia, United States
Evaluation of Sonelokimab in Patients with Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
Phase 3
Recruiting
- Conditions
- Arthritis, Psoriatic
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- MoonLake Immunotherapeutics AG
- Target Recruit Count
- 600
- Registration Number
- NCT06641089
- Locations
- 🇺🇸
Clinical Site, Lubbock, Texas, United States
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Phase 3
Active, not recruiting
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- MoonLake Immunotherapeutics AG
- Target Recruit Count
- 422
- Registration Number
- NCT06411899
- Locations
- 🇬🇧
Clinical Site, Salford, United Kingdom
🇩🇪Clinical SIte, Halle/ Saale, Germany
Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Phase 3
Active, not recruiting
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- MoonLake Immunotherapeutics AG
- Target Recruit Count
- 418
- Registration Number
- NCT06411379
- Locations
- 🇪🇸
Clinical Site, Valencia, Spain
🇫🇷Clinical SIte, Brest, France
Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis
Phase 2
Completed
- Conditions
- Arthritis, Psoriatic
- Interventions
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- MoonLake Immunotherapeutics AG
- Target Recruit Count
- 207
- Registration Number
- NCT05640245
- Locations
- 🇵🇱
Clinical SIte, Wrocław, Poland
🇪🇸Clinical Site, Sevilla, Spain
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
Phase 2
Completed
- Conditions
- Hidradenitis Suppurativa
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- MoonLake Immunotherapeutics AG
- Target Recruit Count
- 234
- Registration Number
- NCT05322473
- Locations
- 🇵🇱
Clinical Site, Łódź, Poland
© Copyright 2025. All Rights Reserved by MedPath